Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study
Veterinary Ophthalmology · 2024
DOI: 10.1111/vop.13190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Ophthalmology, 2024. Verfasst von Rodrigo García-Santisteban und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Veterinario Oftalvet, Mexico City, Mexico. Hauptthemen laut MEDLINE: Keratoconjunctivitis Sicca, Cyclosporine, Tacrolimus, Dog Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Purpose
To compare the safety and efficacy of a 100 microgram subconjunctival injection of liposome‐encapsulated sirolimus (SCJS) to cyclosporine (CsA) or tacrolimus (CsA/T) for the treatment of keratoconjunctivitis sicca (KCS) in dogs.
Methods
Dogs with signs and symptoms of KCS were block‐randomized to one of two treatment groups: Biweekly SCJS or conventional treatment (CsA/T). Schirmer tear test 1 (STT‐1) scores, conjunctival hyperemia (CH) scores, corneal opacity (CO) scores, and clinical evaluation of potential side effects were recorded every 2 weeks for 14 weeks for both groups. Differences between groups were analyzed using the mixed results ANOVA and U‐Mann Whitney tests ( p < .05 was considered significant).
Results
A total of 30 eyes were included in the study, of which 20 eyes completed follow‐up. There was no statistically significant interaction between the treatment group and time on STT‐1 score ( p = .165 ), and median CH and CO scores showed no statistically significant differences between groups ( p = .353 and p = .393, respectively). There were no clinically significant side effects present in any subject at any time.
Conclusion
In this trial, a 1 mg/mL (100 micrograms) SCJS every 2 weeks showed similar safety and efficacy profiles as daily CsA/T in dogs with KS after 14 weeks of treatment. Larger studies should be performed to further assess SCJS as an alternative treatment for KCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Veterinario Oftalvet, Mexico City, Mexico.
- Laboratorio Santgar, Mexico City, Mexico.
- University of Florida, Gainesville, Florida, USA.
- Brookseyes LLC, Alachua, Florida, USA.
ORCID-Profile: Rodrigo García-Santisteban
Zitieren
APA
García-Santisteban, R., Linares-Alba, M. A., Botello-Bárcenas, A., Margay, P., Soto, C., Fonzar-Furtado, J., Brooks, D., García, D., & Sánchez, G. A. G. (2024). Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study. Veterinary Ophthalmology. https://doi.org/10.1111/vop.13190
Vancouver
García-Santisteban R, Linares-Alba MA, Botello-Bárcenas A, Margay P, Soto C, Fonzar-Furtado J, et al. Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study. Veterinary Ophthalmology. 2024. doi:10.1111/vop.13190
BibTeX
@article{GarcaSantisteban2024,
author = {García-Santisteban, Rodrigo and Linares-Alba, Mónica Anayatzin and Botello-Bárcenas, Andrés and Margay, Paola and Soto, Carlos and Fonzar-Furtado, Joice and Brooks, Dennis and García, Diego and Sánchez, Gustavo Adolfo García},
title = {Subconjunctival liposomal sirolimus vs. cyclosporine or tacrolimus as treatment of keratoconjunctivitis sicca in dogs: A double‐blind, randomized study},
journal = {Veterinary Ophthalmology},
year = {2024},
doi = {10.1111/vop.13190}
}
EUVIMED